Ce qui a changé

Premier essai de phase 2 enregistré : NCT07749716 — Phase II Clinical Study of VC005 Tablets in Subjects With Severe Alopecia Areata

Premier essai de phase 3 enregistré : NCT07516561 — Efficacy and Safety of APSMNF in the Treatment of Male Androgenetic Alopecia

Premier essai de phase 3 enregistré : NCT07435012 — Androgenic Alopecia TH07 Clinical Trial

Registered on ClinicalTrials.gov as NCT07618195: Study of EPI-001 in Patients With Androgenetic Alopecia

Premier essai de phase 2 enregistré : NCT06562894 — Study to Evaluate Safety and Efficacy of SYHX1901 Tablets in Severe Alopecia Areata Patients

Premier essai de phase 3 enregistré : NCT06916793 — A Phase 3 Study to Evaluate the Safety and Efficacy of CKD-843 in Male Patients With Androgenetic Alopecia

Premier essai de phase 3 enregistré : NCT06972264 — Safety and Efficacy of VDPHL01 in Males With AGA

Premier essai de phase 3 enregistré : NCT06501924 — Clinical Study of DA-002 and DA-005 As a Treatment for Hair Loss

Premier essai de phase 3 enregistré : NCT05824065 — Efficacy and Safety of OMA102 in the Treatment of Female Pattern Hair Loss

Premier essai de phase 2/3 enregistré : NCT06724614 — Efficacy and Safety of VDPHL01 in Males With AGA

Premier essai de phase 3 enregistré : NCT05888922 — Evaluation of Efficacy and Safety of Oral Minoxidil 1 mg in Female Androgenetic Alopecia

Premier essai de phase 2 enregistré : NCT06527365 — Safety and Efficacy of VDPHL01 in Males and Females With AGA

Premier essai de phase 2 enregistré : NCT06444451 — A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT06393452 — Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA

Premier essai de approved enregistré : NCT06240351 — A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)

Premier essai de phase 3 enregistré : NCT06012240 — A Study to Evaluate the Safety and Effectiveness of Upadacitinib Tablets in Adult and Adolescent Participants With Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT06118866 — A Study to Assess the Efficacy and Safety of HMI-115 in Male Subjects With Androgenetic Alopecia

Premier essai de phase 3 enregistré : NCT05910450 — A Study to Evaluate the Efficacy and Safety of Clascoterone Solution in Treatment of Male Pattern Hair Loss

Premier essai de phase 2 enregistré : NCT05865041 — Investigate the Efficacy and Safety of Farudodstat Compared With Its Placebo in Adult Alopecia Areata Participants

Premier essai de phase 2 enregistré : NCT06692465 — To Evaluate the Efficacy and Safety of GT20029 Solution in the Treatment of Androgenetic Alopecia (AGA) in Chinese Adult Males

Premier essai de phase 2 enregistré : NCT05778825 — A Study of Oral Minoxidil to Treat Hair Loss in Children, Teens, and Young Adults Who Are Cancer Survivors

Premier essai de phase 2 enregistré : NCT05802173 — Study of TDM-105795 Following Topical Administration in Male Subjects With Androgenetic Alopecia

Premier essai de phase 3 enregistré : NCT04880889 — BL3000 Compared to Pantogar® in the Treatment of Telogen Effluvium in Women.

Premier essai de phase 2 enregistré : NCT05677438 — A Phase 2 Study to Evaluate the Safety and Efficacy of CKD-498 in Female Patients With Androgenetic Alopecia

Premier essai de phase 1/2 enregistré : NCT05636904 — Safety and Efficacy Study of Topical DLQ01 in the Treatment of Androgenetic Alopecia (AGA) in Men

Premier essai de phase 2 enregistré : NCT05556265 — A Study to Evaluate Efficacy and Safety of Deucravacitinib in Participants With Alopecia Areata

Premier essai de phase 1 enregistré : NCT05324293 — To Evaluate the Safety, Tolerability and Efficacy in Male and Female with AGA Treated with HMI-115 Over a 24-week Treatment Period

Premier essai de phase 2 enregistré : NCT05368103 — Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Premier essai de phase 3 enregistré : NCT05470413 — Evaluate the Efficacy and Safety of SHR0302 in Adult Patients With Severe Alopecia Areata

Premier essai de phase 3 enregistré : NCT06126965 — Phase III Study of KX-826 With Adult Male Patients With AGA

Premier essai de phase 2 enregistré : NCT05205070 — A Study to Evaluate the Efficacy and Safety of Rosnilimab (ANB030) in Treatment of Subjects With Moderate-to-Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT03532958 — Phase 2 Trial of BNZ-1 in Patients With Moderate to Severe Alopecia Areata

Premier essai de phase 3 enregistré : NCT05051761 — Study to Evaluate the Safety and Efficacy of Jaktinib in Adults With Alopecia Areata

Premier essai de phase 1 enregistré : NCT06468579 — To Evaluate the Safety, Tolerability and PK of GT20029 Gel and Solution in Healthy Subjects

Premier essai de phase 3 enregistré : NCT04825561 — A Study to Evaluate the Efficacy and Safety of AD-208

Premier essai de phase 1 enregistré : NCT04805606 — A Clinical Traial to Assess Pharmacokinetic/Pharmacodynamic Profiles and Safety of CKD-843

Premier essai de phase 1 enregistré : NCT04913519 — A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)

Premier essai de phase 3 enregistré : NCT04518995 — Study to Evaluate the Efficacy and Safety of CTP-543 in Adults With Moderate to Severe Alopecia Areata (THRIVE-AA1)

Premier essai de phase 2 enregistré : NCT05940506 — Phase II Study Evaluating the Efficacy and Safety of KX-826

Premier essai de phase 2 enregistré : NCT04556734 — Safety and Efficacy of Oral Etrasimod in Adult Participants With Moderate-to-Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT04346316 — A Phase II Study in Patients With Alopecia Areata

Premier essai de phase 1 enregistré : NCT04214808 — To Evaluate the Pharmacokinetics and Safety of AD-208

Premier essai de phase 2 enregistré : NCT04034134 — Study to Evaluate the Safety and Efficacy ofJaktinib Hydrochloride Tablets in Severe Alopecia Areata

Premier essai de phase 3 enregistré : NCT04006457 — Long-Term PF-06651600 for the Treatment of Alopecia Areata

Premier essai de phase 3 enregistré : NCT03899259 — A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

Premier essai de phase 2/3 enregistré : NCT03898479 — Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata

Premier essai de phase 1 enregistré : NCT04984707 — Safety, Tolerability and Pharmacokinetics of KX826 in Healthy Male Subjects With Androgenetic Alopecia Following Topical Single Ascending Dose Administration

Premier essai de phase 2/3 enregistré : NCT03732807 — PF-06651600 for the Treatment of Alopecia Areata

Premier essai de phase 2/3 enregistré : NCT03742518 — A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia

Premier essai de phase 2/3 enregistré : NCT03570749 — A Study of Baricitinib (LY3009104) in Participants With Severe or Very Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT03594227 — ATI-501 Oral Suspension Compared to Placebo in Subjects With Alopecia Areata, Alopecia Universalis or Alopecia Totalis

Premier essai de phase 2 enregistré : NCT03467412 — To Investigate Efficacy of FOL-005 on Hair Growth on Scalp Skin

Premier essai de phase 2 enregistré : NCT03354637 — A Study of ATI-50002 Topical Solution for the Treatment of Alopecia Areata

Premier essai de phase 2 enregistré : NCT03137381 — Study to Evaluate the Safety and Efficacy of CTP-543 in Adults With Moderate to Severe Alopecia Areata

Premier essai de phase 2 enregistré : NCT02974868 — Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Premier essai de phase 2 enregistré : NCT02974868 — Study To Evaluate The Efficacy And Safety Profile Of PF-06651600 And PF-06700841 In Subjects With Alopecia Areata

Premier essai de phase 2 enregistré : NCT02919735 — Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)

Premier essai de phase 3 enregistré : NCT03004469 — Study to Evaluate the Efficacy and Safety of P-3074 Topical Solution in the Treatment of Androgenetic Alopecia

Premier essai de phase 1/2 enregistré : NCT02793557 — Investigation of FOL-005 on Clinical Safety and Effect on Hair Growth

Premier essai de phase 2 enregistré : NCT02561585 — LEO 124249 Ointment in the Treatment of Alopecia Areata

Premier essai de phase 2 enregistré : NCT02275351 — A Study of the Safety, Tolerability, and Efficacy of Topical SM04554 Solution in Male Subjects With Androgenetic Alopecia (AGA)

Premier essai de phase 3 enregistré : NCT00441116 — A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia